热炎宁合剂联合利奈唑胺增强抗MRSA肺炎疗效的实验研究
该研究在大鼠MRSA肺炎模型中探讨热炎宁合剂(RYN)单用及联合利奈唑胺的药效与机制。结果显示RYN减轻肺损伤和炎症,联合用药疗效优于单用,机制涉及抑制TLR2/NF-κB/NLRP3通路及增强利奈唑胺对MRSA的抑制和清除。
要点
- RYN可减轻MRSA肺炎大鼠的肺损伤和炎症。
- RYN联合利奈唑胺疗效优于任一单药治疗。
- RYN抗炎作用与抑制TLR2/NF-κB/NLRP3通路相关。
核心结论
- RYN可能作为抗生素辅助药物治疗MRSA相关肺炎。
研究设计与样本
- 在大鼠MRSA诱导肺炎模型中研究RYN单用及联合利奈唑胺的药效。
- 采用转录组学、ELISA、Western blot和qRT-PCR探索并验证抗炎机制。
- 采用UPLC-MS和分子对接探索RYN抗炎活性成分。
主要发现
- RYN减轻肺炎大鼠肺损伤和炎症。
- RYN联合利奈唑胺的疗效优于任一单药治疗。
- 协同疗效可能与RYN抑制炎症反应及增强利奈唑胺对肺组织MRSA的抑制和清除有关。
- RYN通过抑制TLR2/NF-κB/NLRP3通路发挥抗炎作用,7种活性成分可能起主导作用。
临床怎么用
- 在MRSA肺炎治疗中,可考虑RYN作为利奈唑胺的辅助用药以增强疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The Reyanning Mixture (RYN) is a Chinese patent medicine widely used in the treatment of respiratory inflammatory diseases in China and has potential in the treatment of bacteria-infected pneumonia. AIM OF THE STUDY: The present study aimed to demonstrate the therapeutic potential of RYN in combination with linezolid for the treatment of MRSA-infected pneumonia and to explore the mechanisms of action and active components. MATERIALS AND METHODS: The pharmacodynamics of RYN alone and in combination with linezolid was investigated in a rat model of MRSA-induced pneumonia. Transcriptomics, ELISA, Western blot and qRT-PCR were used to explore and verify the pharmacological mechanism of the anti-inflammatory effect of RYN. UPLC-MS and molecular docking were used to explore the anti-inflammatory components of RYN for the treatment of MRSA-infected pneumonia. RESULTS: In vivo, RYN reduced lung injury and inflammation in rats with pneumonia. In particular, the combination of RYN and linezolid enhanced the therapeutic effect compared to that of either treatment alone. Further research suggests that the synergistic therapeutic effect of the combination may be related to the inhibition of the inflammatory response by RYN and the enhancement of linezolid inhibition and clearance of MRSA in lung tissues by RYN. RYN plays an anti-inflammatory role in MRSA-infected pneumonia by inhibiting the TLR2/NF-κB/NLRP3 pathway, with 7 active components that may play a dominant role. CONCLUSIONS: These results indicate that RYN may serve as an adjuvant drug to antibiotics for the treatment of MRSA-associated pneumonia. Exploration of its mechanisms and active components is conducive to the clinical application and quality improvement of RYN. More importantly, this study showed that the synergistic therapeutic effect of the combination of traditional Chinese medicine and antibiotics may be a valuable therapeutic strategy.
引用
- Dou MH, Huang JY, Li PY, et al. How can traditional Chinese medicine enhance the efficacy of antibiotics in the treatment of MRSA-infected pneumonia: An experimental study on the combination of Reyanning mixture (RYN) and linezolid. J Ethnopharmacol. 2024. PMID: 39653103. doi:10.1016/j.jep.2024.119221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。